New York Assembly Bill A02253

New York 2025-2026 Regular Session

• Introduced: 1/16/25
• Refer: 1/16/25
• Refer: 1/7/26

Caption

Relates to dispensing certain controlled substances for use by a person with a substance use disorder during certain emergency medical treatment, or to relieve acute withdrawal symptoms.

Impact

The implications of A02253 could significantly enhance the pathways available for medical practitioners, including registered nurses and emergency medical technicians, to provide timely and essential care to patients suffering from substance use disorders. By broadening the circumstances under which controlled substances can be administered, the bill seeks to address both immediate medical needs and long-term recovery processes for affected individuals. This could also lead to reduced healthcare complications associated with withdrawal symptoms, thereby potentially decreasing hospital admissions related to such issues.

Summary

Bill A02253 proposes amendments to the public health law concerning the dispensing of controlled substances to individuals with substance use disorders. Specifically, it allows these substances to be prescribed and administered during emergency medical situations not related to the substance use disorder itself, as well as to facilitate the relief of acute withdrawal symptoms for patients within certain categories. This law aims to provide critical support for individuals in distress, particularly during medical emergencies or when coping with severe health issues.

Contention

While the bill may also enjoy support from healthcare advocates who recognize the desperate needs of individuals battling addiction, there may be concerns from other stakeholders regarding the complexities of prescription practices and public safety. Critics may argue that increasing access to controlled substances, even in emergency contexts, could inadvertently lead to misuse or related health risks if proper safeguards are not firmly established. As such, discussions around the balance between necessary medical intervention and the potential for regulatory overreach are likely to arise during legislative considerations of A02253.